The goal of this workshop is to explore new approaches for addressing the issues in developing novel therapeutics and technologies for the treatment of Alzheimer’s disease. To that end, we want to avoid re-hashing the current state of the field and would like everyone to assume that all attendees are already familiar with the background, science, and issues. We’ve put together the following selection of readings to help ensure that everyone is on the same page and strongly encourage you to familiarize yourself with the material, as needed, in advance.
- A Path Toward Understanding Neurodegeneration. Kenneth S. Kosik, Terrence J. Sejnowski, Marcus E. Raichle, Aaron Ciechanover, and David Baltimore, 2016, Science 353(6302), pp. 872–873.
- Alzheimer’s Disease. Colin L. Masters, Randall Bateman, Kaj Blennow, Christopher C. Rowe, Reisa A. Sperling, and Jeffrey L. Cummings, 2015, Nature Reviews Disease Primers 1, Article No. 150156.
- Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders: Workshop Summary. Forum on Neuroscience and Nervous System Disorders; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy; Institute of Medicine. Washington (DC): National Academies Press (US); 2015 Oct 22. doi: 10.17226/21732
- Alzheimer’s Disease Drug-Development Pipeline: Few Candidates, Frequent Failures. Jeffrey L. Cummings, Travis Morstorf, and Kate Zhong, 2014, Alzheimer’s Research & Therapy 6(4): 37.
- Parallel Discovery of Alzheimer’s Therapeutics. Andrew W. Lo, Carole Ho, Jayna Cummings, and Kenneth S. Kosik, 2014, Science Translational Medicine 6 (241), pp. 241cm5.
- Multicompany Trials Adapt to Disciplines Beyond Cancer. Asher Mullard, 2014, Nature Medicine 20 (3), doi:10.1038/nm0114-3.
Selected articles from Neuron Special Issue: Bridging the Gap between Basic Research Discoveries and Clinical Applications, 2014, Volume 84, Issue 3.
- NINDS Translational Programs: Priming the Pump of Neurotherapeutics Discovery and Development by Rajesh Ranganathan, pp. 515–520.
- Collaboration in Translational Neuroscience: A Call to Arms by Adrian J. Ivinson, pp. 521–525.
- Transforming Our Approach to Translational Neuroscience: The Role and Impact of Charitable Nonprofits in Research by Cynthia Joyce, pp. 526–532.
- Public-Private Partnership: A New Engine for Translational Research in Neurosciences by Declan G. M. Murphy, Michel Goldman, Eva Loth, and Will Spooren, pp. 533–536.
- Improving and Accelerating Drug Development for Nervous System Disorders by Diana E. Pankevish, Bruce M. Altevogt, John Dunlop, Fred H. Gage, and Steve E. Hyman, pp. 546–553.
- Medicines for the Mind: Policy-Based “Pull” Incentives for Creating Breakthrough CNS Drugs by Dennis W. Choi, Robert Armitage, Linda S. Brady, Timothy Coetzee, William Fisher, Steve Hyman, Atul Pande, Steven Paul, William Potter, Benjamin Roin, Todd Sherer, pp. 554–563.
- Rigor or Mortis: Best Practices for Preclinical Research in Neuroscience by Oswald Steward and Rita Balice-Gordon, pp. 572–581.
- How Clinical Development Can, and Should, Inform Translational Science by Melissa Barker-Haliski, Daniel Friedman, H. Steve White, and Jacqueline A. French, pp. 582–583.
- Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases by Alice S. Chen-Plotkin, pp. 594–607.
- The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials by Reisa Sperling, Elizabeth Mormino, and Keith Johnson, pp. 608–622.